Ashwani Verma
Stock Analyst at UBS
(4.52)
# 1,025
Out of 4,572 analysts
215
Total ratings
59.7%
Success rate
14%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Downgraded: Hold | $49 → $28 | $22.22 | +26.01% | 9 | Jul 24, 2026 | |
| VTRS Viatris | Maintained: Buy | $20 → $23 | $17.24 | +33.41% | 6 | Jul 21, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $669 | $544.51 | +22.86% | 1 | Jul 21, 2026 | |
| MPLT MapLight Therapeutics | Rated: Buy | $48 → $52 | $36.56 | +42.23% | 2 | Jul 21, 2026 | |
| AMRX Amneal Pharmaceuticals | Maintained: Buy | $23 | $17.92 | +28.35% | 3 | Jul 15, 2026 | |
| EXEL Exelixis | Rated: Hold | $40 → $52 | $55.37 | -6.09% | 9 | Jul 2, 2026 | |
| CRNX Crinetics Pharmaceuticals | Initiated Coverage: Buy | $55 | $83.73 | -34.31% | 1 | Jul 2, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $307 | $253.87 | +20.93% | 15 | Jul 1, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $161 → $208 | $175.77 | +18.34% | 18 | Jun 30, 2026 | |
| CYTK Cytokinetics | Upgraded: Buy | $69 → $115 | $80.74 | +42.43% | 13 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $30.81 | +36.32% | 28 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $103 → $113 | $117.67 | -3.97% | 12 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $166 | $106.92 | +55.26% | 7 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $14.32 | -23.18% | 6 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $95 → $72 | $95.36 | -24.50% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $48 | $52.89 | -9.25% | 7 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 → $57 | $58.83 | -3.11% | 11 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $259 | $241.00 | +7.47% | 12 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $6 | $3.06 | +96.08% | 3 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $645 → $705 | $528.47 | +33.40% | 19 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $40 | $24.84 | +61.03% | 10 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,080 | $1,196.03 | -9.70% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $220 | $259.36 | -15.18% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $43 | $35.32 | +21.74% | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 | $39.41 | -54.33% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.05 → $1.1 | $1.41 | n/a | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $119 → $130 | $202.19 | n/a | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $3.19 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.8509 | n/a | 1 | Oct 11, 2022 |
Legend Biotech
Jul 24, 2026
Downgraded: Hold
Price Target: $49 → $28
Current: $22.22
Upside: +26.01%
Viatris
Jul 21, 2026
Maintained: Buy
Price Target: $20 → $23
Current: $17.24
Upside: +33.41%
Madrigal Pharmaceuticals
Jul 21, 2026
Maintained: Buy
Price Target: $669
Current: $544.51
Upside: +22.86%
MapLight Therapeutics
Jul 21, 2026
Rated: Buy
Price Target: $48 → $52
Current: $36.56
Upside: +42.23%
Amneal Pharmaceuticals
Jul 15, 2026
Maintained: Buy
Price Target: $23
Current: $17.92
Upside: +28.35%
Exelixis
Jul 2, 2026
Rated: Hold
Price Target: $40 → $52
Current: $55.37
Upside: -6.09%
Crinetics Pharmaceuticals
Jul 2, 2026
Initiated Coverage: Buy
Price Target: $55
Current: $83.73
Upside: -34.31%
Jazz Pharmaceuticals
Jul 1, 2026
Maintained: Buy
Price Target: $307
Current: $253.87
Upside: +20.93%
Neurocrine Biosciences
Jun 30, 2026
Maintained: Buy
Price Target: $161 → $208
Current: $175.77
Upside: +18.34%
Cytokinetics
Jun 29, 2026
Upgraded: Buy
Price Target: $69 → $115
Current: $80.74
Upside: +42.43%
Jun 26, 2026
Maintained: Buy
Price Target: $42
Current: $30.81
Upside: +36.32%
Jun 25, 2026
Maintained: Hold
Price Target: $103 → $113
Current: $117.67
Upside: -3.97%
Jun 3, 2026
Reiterated: Buy
Price Target: $166
Current: $106.92
Upside: +55.26%
May 28, 2026
Reiterated: Hold
Price Target: $11
Current: $14.32
Upside: -23.18%
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $95.36
Upside: -24.50%
May 6, 2026
Maintained: Buy
Price Target: $42 → $48
Current: $52.89
Upside: -9.25%
Apr 20, 2026
Maintained: Buy
Price Target: $49 → $57
Current: $58.83
Upside: -3.11%
Apr 10, 2026
Rated: Buy
Price Target: $251 → $259
Current: $241.00
Upside: +7.47%
Mar 24, 2026
Rated: Buy
Price Target: $10 → $6
Current: $3.06
Upside: +96.08%
Mar 5, 2026
Rated: Buy
Price Target: $645 → $705
Current: $528.47
Upside: +33.40%
Jan 5, 2026
Maintained: Buy
Price Target: $35 → $40
Current: $24.84
Upside: +61.03%
Nov 7, 2025
Maintained: Buy
Price Target: $1,080
Current: $1,196.03
Upside: -9.70%
Nov 7, 2025
Maintained: Hold
Price Target: $220
Current: $259.36
Upside: -15.18%
Oct 14, 2025
Maintained: Buy
Price Target: $50 → $43
Current: $35.32
Upside: +21.74%
Jul 29, 2025
Maintained: Hold
Price Target: $18
Current: $39.41
Upside: -54.33%
Jul 21, 2025
Maintained: Hold
Price Target: $1.05 → $1.1
Current: $1.41
Upside: n/a
Jul 14, 2025
Maintained: Hold
Price Target: $119 → $130
Current: $202.19
Upside: n/a
Jun 17, 2025
Maintained: Buy
Price Target: $5
Current: $3.19
Upside: n/a
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.8509
Upside: n/a